Navigation Links
Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results

TUSTIN, Calif., Dec. 4/PRNewswire-FirstCall/ --Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the second quarter of fiscal year 2009 on December 10, 2008 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same day.

Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2008 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EST/ 8:30 a.m. PST.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through December 17, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (, which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

    GendeLLindheim BioCom Partners
    (800) 987-8256

    Barbara Lindheim
    (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
4. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
6. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
8. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
9. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
10. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
11. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):